PV-1950D

**PV-1950D** is a DNA vaccine based on the MultiTEP platform, designed to target three specific B-cell epitopes (amino acids 85–99, 109–126, and 126–140) of pathological human α-synuclein (hα-Syn), a protein central to synucleinopathies. It encodes a minigene with three copies of each epitope fused to a string of 12 universal CD4 T-cell epitopes (MultiTEP) in a pVAX1 vector, administered via intramuscular injection followed by electroporation. Developed by researchers at the Institute for Molecular Medicine, it induces high-titer antibodies that bind pathological hα-Syn, reducing its accumulation (including protein kinase-resistant forms), ameliorating neurodegeneration, and improving motor deficits in D-line transgenic mouse models of Parkinson's disease (PD) and dementia with Lewy bodies (DLB), with sex-dependent efficacy (stronger in females for some outcomes). Selected as the most immunogenic and effective among related vaccines (e.g., PV-1949D) for future IND-enabling studies.[1][2][3]